Saba Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Saba Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-692,960	Closed	-$6.89M	–	786
2021 Q3	$6.89M	Hold	692,960	–	–	0.17%	162
2021 Q2	$6.85M	Buy	692,960 +27,865	+4%	+$273K	0.2%	120
2021 Q1	$6.38M	Buy	+665,095	New	+$6.42M	0.2%	95

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SGA

SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Saba Capital Management's PEAR Position: Q4 2021 in Review

Saba Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 692,960 shares — an estimated $6.89M sold.

Saba Capital Management first reported a position in PEAR in Q1 2021 and held it in 3 quarters. The position peaked at $6.89M in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

Saba Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Saba Capital Management sold 692,960 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $6.89M.
Saba Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
Saba Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $6.89M in Q3 2021.
25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on Saba Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.